Zoekresultaten - You searched for Publication

96 results

Biocartis Group NV: Biocartis announces publication of its 2017 annual report

Read more

Publication in accordance with article 14 of the law of May 2007 regarding the publication of major shareholdings (the "Transparency Law")

Read more

Publication in accordance with art. 14 of the Belgian Law regarding the publication of major shareholdings (the "transparancy law")

Read more

Biocartis Group NV: Biocartis announces publication of 2016 Annual Report

Read more

argenx announces publication of preclinical data supporting the therapeutic potential of SIMPLE AntibodyTM ARGX-116

Read more

Ablynx: publication in accordance with article 14 of the Belgian law regarding the publication of major shareholdings

Read more

Ablynx - Publication in accordance with art.14 of the Belgian law of 2/05/2017 regarding the publication of major shareholdings (the "transparancy law")

Read more

Ablynx - Publication in accordance with art.14 of the Belgian Law of 2/5/2007 regarding the publication of major shareholdings (the "transparancy law")

Read more

Ablynx - Publication in accordance with art.14 of the Belgian Law of 2/5/2007 regarding the publication of major shareholdings (the "transparancy law")

Read more

Ablynx - Publication in accordance with §14 of the Belgian law of 2/5/2007 regarding the publication of major shareholdings (the "transparancy" law)

Read more

Ablynx - Publication in accordance with §14 of the Belgian law of 2/5/2007 regarding the publication of major shareholdings (the "transparancy" law)

Read more

Ablynx - Publication in accordance with §14 of the Belgian law of 2/5/2007 regarding the publication of major shareholdings (the "transparancy" law) (1)

Read more

Ablynx: publication regarding the publication of major shareholdings

Read more

Ablynx: publication regarding the publication of major shareholdings (the "transparancy law")

Read more

Ablynx: publication regarding the publication of major shareholdings (the "transparancy law")

Read more

Ablynx - Publication in accordance with §14 of the Belgian law of 2/5/2007 regarding the publication of major shareholdings (the "transparancy" law)

Read more

TiGenix announces publication in Gastroenterology of 52-week results of the Phase III ADMIRE-CD trial of Cx601 (darvadstrocel) in the treatment of complex perianal fistulas in Crohn’s disease

Read more

Ablynx - Publication in accordance with §14 of the Belgian law of 2/5/2007 regarding the publication of major shareholdings (the "transparancy" law)

Read more

Ablynx - Publication in accordance with §14 of the Belgian law of 2/5/2007 regarding the publication of major shareholdings (the "transparancy" law)

Read more

argenx announces publication of full data from Phase 1 healthy volunteer study of efgartigimod in Journal of Clinical Investigation

Read more

Ablynx - Correction of Publication in accordance with §14 of the Belgian law of 2/5/2007 regarding the publication of major shareholdings (the "transparancy" law)

Read more

ThromboGenics announces publication in Experimental Eye Research of preclinical data supporting therapeutic potential of THR-317 in DR

Read more

Galapagos publication of the annual report and invitation to the annual shareholders' meeting

Read more

ThromboGenics announces publication in The Journal of Medicinal Chemistry of preclinical data

Read more

TiGenix Transparency notifications pursuant to Article 14 of the Law of May 2, 2007

Read more

GLPG1690 results in IPF published in The Lancet Respiratory Medicine and presented at ATS

Read more

Biocartis Group NV: Biocartis' Idylla(TM) Instrument and Idylla(TM) Console exempt from US FDA 510(k) notification requirements

Read more

Publication of a Transparency Notification Received by Mithra Pharmaceuticals sa/nv

Read more

Galapagos: Positive trial results with filgotinib in psoriatic arthritis and ankylosing spondylitis both published in the lancet

Read more

Mithra Pharmaceuticals publie son rapport annuel 2016 et l’invitation à son Assemblée Générale Ordinaire des actionnaires

Read more

FDA grants Fast Track Designation for Celyad’s ischemic heart failure therapy, C-Cure®

Read more

MDxHealth Shareholder Transparency Notification

Read more

Biocartis Group NV: Study demonstrating high performance of Idylla(TM) liquid biopsy RAS tests to be presented at ASCO Annual Meeting

Read more

TiGenix: Transparency Information

Read more

Biocartis Group NV: Strong performance data of proprietary MSI Biomarkers for the Idylla(TM) MSI Test to be published at ESMO

Read more

ThromboGenics Business Update - Q3 2017

Read more

argenx reports third quarter 2017 financial results and provides business update

Read more

JPMorgan Chase & Co notifies 3.12% shareholding in TiGenix

Read more

Ablynx - Publication in accordance with §14 of the Belgian Law

Read more

The Adecco Group Announces the Acquisition of CMAST

Read more

Patient Enrolment in Phase II CIRCLE Study Evaluating THR-409 (ocriplasmin) for Non-Proliferative Diabetic Retinopathy (NPDR) Discontinued due to Slow Recruitment Rate

Read more

New start-up Aelin Therapeutics secures 27M Euros to pioneer the development of a novel drug modality

Read more

argenx announces launch of proposed public offering in the United States

Read more

Bone Therapeutics Launches Equity Placement

Read more

TiGenix Transparency notification pursuant to Article 14 of the Law of May 2, 2007

Read more

VIB, CD3 and Galapagos NV enter into a license deal for the development of MALT1 inhibitors

Read more

TiGenix - Transparency Information

Read more

TiGenix - Transparency notifications pursuant to Article 14 of the Law of May 2, 2007

Read more

Ablynx announces 2017 full year results

Read more

MDxHealth financial results

Read more

Bone Therapeutics announces private placement of convertible bonds

Read more

Previously announced tender offers by Sanofi to acquire Ablynx will commence on april 4, 2018

Read more

Mithra releases 2017 Annual Report and invitation to its Ordinary General Shareholders' Meeting

Read more

Bone Therapeutics Information on the total number of voting rights and shares

Read more

GST raises EUR 5 million to develop veterinary stem cell products

Read more

Biocartis: Two Performance Studies on Idylla(TM) MSI Biomarkers Selected for Publication at ASCO Conference

Read more

Webinar: A comprehensible jumpstart towards gcp computer system validation anno 2018

Read more

Ablynx: Notice In Relation To The Convertible Bonds Due May 2020

Read more

Bone Therapeutics: Information on the total number of voting rights and shares

Read more

Biocartis Group NV: Study Demonstrates Ability of Idylla(TM) EGFR Mutation Test to Produce a Result in 80% of Failed Next Generation Sequencing Lung Cancer Tests

Read more

Mithra launches capital increase by means of a private placement via an accelerated bookbuild offering

Read more

Bone Therapeutics: Information on the total number of voting rights and shares

Read more

Biocartis Group NV: Study Reviewing 2,500 Performed Idylla(TM) Tests Shows Generation of Valid Results in 98.1% of Cases and Outperformance over Reference Methods

Read more

MDxHealth's SelectMDx Test Successfully Stratifies Men

Read more

CMAST: Horizon Europe – looking at the future or building on the past?

Read more

TiGenix: Transparency Information

Read more

Mithra: Publication of a Transparency Notification Received from François Fornieri

Read more

MDxHealth (R): Medicare Establishes Final Positive Local Coverage Determination for Use of ConfirmMDx for Prostate Cancer

Read more

Dr. Margo Roberts joins Celyad’s Board of Directors and Scientific Committee

Read more

Bone Therapeutics: Information on the total number of voting rights and shares

Read more

argenx announces launch of proposed public offering in the United States

Read more

argenx announces closing of U.S. public offering for gross proceeds of approximately $300.6 million

Read more

Bone Therapeutics: Information on the total number of voting rights and shares

Read more

ONTOFORCE and ChemAxon facilitate linked chemical data search

Read more

ERS Genomics and Syngulon Sign License Agreement on CRISPR-Cas9 Genome Editing Patents for Industrial Applications

Read more

TiGenix reports 2016 full year results

Read more

Biocartis Group NV: Biocartis Q1 2017 Business Update

Read more

Celyad initiates second dose escalation in THINK trial in first US patient

Read more

argenx announces launch of proposed initial public offering in the United States

Read more

Helena Biosciences to develop automated blood test for chronic liver disease based on VIB and Ghent University research

Read more

argenx raises approximately $100 million gross proceeds with NASDAQ IPO

Read more

argenx announces full exercise of underwriters' option to purchase additional ADSs

Read more

argenx announces closing of NASDAQ IPO

Read more

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

Read more

Mithra Launches a Capital Increase by Means of a Private Placement via an Accelerated Bookbuild Offering

Read more

Celyad publishes additional pre-clinical data in support of THINK trial

Read more

Celyad announces initiation of the SHRINK trial

Read more

argenx reports second quarter business update and half-year 2017 financial results

Read more

MDxHealth Announces First Half 2017 Financial Results

Read more

Biocartis announces H1 2017 results

Read more

Services

Read more

Do you have to become officially a BIOBANK under the new Belgian law?

Read more

The first veterinary stem cell product recommended for approval in Europe becomes a reality

Read more

Press Release - Life Sciences & Biotechnology - 10/08/2018

Read more

Daily Newsflash - 26/09/2018

Read more

Press Release - Life Sciences & Biotechnologie - 26/10/2018

Read more